Jiwon Sarah Park1, Sarah B Bateni1, Richard J Bold1, Amanda R Kirane1, Daniel J Canter2, Robert J Canter3. 1. Division of Surgical Oncology, Department of Surgery, University of California Davis Medical Center, Sacramento, California. 2. Department of Urology, Ochsner Clinic, New Orleans, Louisiana. 3. Division of Surgical Oncology, Department of Surgery, University of California Davis Medical Center, Sacramento, California. Electronic address: rjcanter@ucdavis.edu.
Abstract
BACKGROUND: The modified frailty index (mFI) is an important method to risk-stratify surgical patients and has been validated for general surgery and selected surgical subspecialties. However, there are currently no data assessing the efficacy of the mFI to predict acute morbidity and mortality in patients undergoing surgery for retroperitoneal sarcoma. METHODS: Using the American College of Surgeons' National Surgical Quality Improvement Program from 2007 to 2012, we performed a retrospective analysis of patients with a diagnosis of primary malignant retroperitoneal neoplasm who underwent surgical resection. The mFI was calculated according to standard published methods. Univariate and multivariate statistical analyses including χ2 and logistic regression were used to identify predictors of 30-d overall morbidity, 30-d severe morbidity (Clavien III/IV), and 30-d mortality. RESULTS: We identified 846 patients with the diagnosis of primary malignant retroperitoneal neoplasm who underwent surgical resection. The distribution mFI scores was 0 (48.5%) or 1 (36.3%), with only 4.5% of patients presenting with a score ≥3. Rates of 30-d overall morbidity, serious morbidity, and mortality were 22.6%, 12.9%, and 1.2%, respectively. Only selected mFI scores were associated with serious morbidity and overall morbidity on multivariate analysis (P < 0.05), and mFI did not predict 30-d mortality (P > 0.05). CONCLUSIONS: Our data demonstrate that the majority of patients undergoing retroperitoneal sarcoma resections have few, if any, comorbidities. The mFI was a limited predictor of overall and serious complications and was not a significant predictor of mortality. Better discriminators of preoperative risk stratification may be needed for this patient population.
BACKGROUND: The modified frailty index (mFI) is an important method to risk-stratify surgical patients and has been validated for general surgery and selected surgical subspecialties. However, there are currently no data assessing the efficacy of the mFI to predict acute morbidity and mortality in patients undergoing surgery for retroperitoneal sarcoma. METHODS: Using the American College of Surgeons' National Surgical Quality Improvement Program from 2007 to 2012, we performed a retrospective analysis of patients with a diagnosis of primary malignant retroperitoneal neoplasm who underwent surgical resection. The mFI was calculated according to standard published methods. Univariate and multivariate statistical analyses including χ2 and logistic regression were used to identify predictors of 30-d overall morbidity, 30-d severe morbidity (Clavien III/IV), and 30-d mortality. RESULTS: We identified 846 patients with the diagnosis of primary malignant retroperitoneal neoplasm who underwent surgical resection. The distribution mFI scores was 0 (48.5%) or 1 (36.3%), with only 4.5% of patients presenting with a score ≥3. Rates of 30-d overall morbidity, serious morbidity, and mortality were 22.6%, 12.9%, and 1.2%, respectively. Only selected mFI scores were associated with serious morbidity and overall morbidity on multivariate analysis (P < 0.05), and mFI did not predict 30-d mortality (P > 0.05). CONCLUSIONS: Our data demonstrate that the majority of patients undergoing retroperitoneal sarcoma resections have few, if any, comorbidities. The mFI was a limited predictor of overall and serious complications and was not a significant predictor of mortality. Better discriminators of preoperative risk stratification may be needed for this patient population.
Authors: Matthew P Doepker; Karim H Hanna; Zachary J Thompson; Odion T Binitie; Douglas G Letson; Ricardo J Gonzalez Journal: J Surg Oncol Date: 2016-01-06 Impact factor: 3.454
Authors: Jessica L Li; Martha A Henderson; Louis M Revenig; John F Sweeney; David A Kooby; Shishir K Maithel; Viraj A Master; Kenneth Ogan Journal: J Surg Res Date: 2016-03-22 Impact factor: 2.192
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Joseph Karam; Athanasios Tsiouris; Alexander Shepard; Vic Velanovich; Ilan Rubinfeld Journal: Ann Vasc Surg Date: 2013-05-24 Impact factor: 1.466
Authors: A C Panayi; A R Orkaby; D Sakthivel; Y Endo; D Varon; D Roh; D P Orgill; R L Neppl; H Javedan; S Bhasin; I Sinha Journal: Am J Surg Date: 2018-11-27 Impact factor: 2.565